The Interplay Between Depression and Cardiovascular Disease: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives

Purpose of Review Depression and cardiovascular disease (CVD) frequently co-occur and contribute substantially to global morbidity and mortality. This narrative review synthesizes current evidence on the biological, psychological, and clinical mechanisms connecting these two conditions. The aim is to clarify the key pathways underlying their bidirectional relationship and to highlight therapeutic strategies that may improve outcomes in individuals affected by both disorders. Recent Findings Recent studies increasingly demonstrate that depression and CVD share multifaceted biological mechanisms, including hypothalamic–pituitary–adrenal axis dysregulation, systemic inflammation, autonomic imbalance, oxidative stress, endothelial dysfunction, and genetic and epigenetic alterations. Immunological activity, particularly cytokine-mediated neuroinflammation, has emerged as a central component linking mood dysregulation with vascular pathology. Behavioral and psychosocial pathways also contribute to cardiovascular risk. Adverse health behaviors, including physical inactivity, poor diet, smoking, substance use, sleep disturbance, and treatment nonadherence, may directly contribute to cardiovascular risk, while psychosocial factors such as chronic stress and social isolation may influence or amplify these behavioral and biological pathways. Additionally, precision-medicine strategies that incorporate genetic, metabolic, and psychosocial profiles are increasingly recognized as important for optimizing individualized care. Summary Depression and CVD are interconnected through a complex web of biological and psychosocial pathways that mutually reinforce disease progression. Understanding these shared mechanisms is critical for improving prevention, diagnosis, and treatment. Integrated, multidisciplinary management, addressing inflammation, autonomic dysfunction, lifestyle factors, and mental health, is essential to reduce morbidity in this high-risk population. Future research should continue exploring biomarkers and personalized interventions to better manage this intertwined comorbidity.